In accordance with such discrepancies, high expression of EpCAM is frequently associated with poor clinical outcome of breast, colorectal, pancreatic, and nasopharyngeal carcinomas and ovarian and bladder cancers [79,81–89] but with a good prognosis of colonic, gastric, and renal cancer [90–92] and of HNSCCs, as shown in the present study. Here, EPCAM is linked to urinary bladder cancer.